Ernexa Therapeutics (ERNA) Competitors $1.95 -0.03 (-1.52%) Closing price 07/3/2025 01:36 PM EasternExtended Trading$1.95 0.00 (0.00%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA vs. IFRX, AVTX, OTLK, CRVO, PMVP, CELU, KLRS, CUE, IPA, and BLUEShould you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include InflaRx (IFRX), Avalo Therapeutics (AVTX), Oncobiologics (OTLK), CervoMed (CRVO), PMV Pharmaceuticals (PMVP), Celularity (CELU), Kalaris Therapeutics (KLRS), Cue Biopharma (CUE), ImmunoPrecise Antibodies (IPA), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. Ernexa Therapeutics vs. Its Competitors InflaRx Avalo Therapeutics Oncobiologics CervoMed PMV Pharmaceuticals Celularity Kalaris Therapeutics Cue Biopharma ImmunoPrecise Antibodies bluebird bio InflaRx (NASDAQ:IFRX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Do analysts rate IFRX or ERNA? InflaRx presently has a consensus price target of $6.60, suggesting a potential upside of 719.88%. Given InflaRx's stronger consensus rating and higher possible upside, research analysts plainly believe InflaRx is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IFRX or ERNA more profitable? InflaRx has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Ernexa Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -64.17% -53.39% Ernexa Therapeutics -7,652.75%N/A -285.71% Which has more volatility and risk, IFRX or ERNA? InflaRx has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 5.3, indicating that its stock price is 430% more volatile than the S&P 500. Does the media refer more to IFRX or ERNA? In the previous week, InflaRx had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 1 mentions for InflaRx and 0 mentions for Ernexa Therapeutics. InflaRx's average media sentiment score of 0.00 beat Ernexa Therapeutics' score of -1.22 indicating that InflaRx is being referred to more favorably in the media. Company Overall Sentiment InflaRx Neutral Ernexa Therapeutics Negative Do institutionals & insiders have more ownership in IFRX or ERNA? 42.4% of InflaRx shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 1.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, IFRX or ERNA? Ernexa Therapeutics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$180K300.22-$49.85M-$0.82-0.98Ernexa Therapeutics$580K24.74-$44.54M-$8.31-0.23 SummaryInflaRx beats Ernexa Therapeutics on 10 of the 16 factors compared between the two stocks. Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.73M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-0.238.9827.5220.22Price / Sales24.74682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book3.904.588.045.67Net Income-$44.54M$31.34M$3.18B$249.13M7 Day Performance5.41%3.25%2.90%3.28%1 Month Performance-28.57%7.08%3.70%5.55%1 Year Performance-93.07%0.17%36.15%21.12% Ernexa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAErnexa Therapeutics0.6656 of 5 stars$1.95-1.5%N/A-92.6%$14.73M$580K-0.2310Negative NewsIFRXInflaRx2.7029 of 5 stars$0.79flat$6.60+735.4%-50.6%$53.03M$180K-0.9660News CoverageAVTXAvalo Therapeutics3.0623 of 5 stars$4.89-2.0%$30.00+513.5%-57.0%$52.96M$440K0.0040News CoverageOTLKOncobiologics1.6785 of 5 stars$1.58-1.6%$9.60+509.5%-74.4%$52.84MN/A-1.7320Positive NewsCRVOCervoMed3.303 of 5 stars$6.06-3.7%$27.63+355.9%-64.0%$52.72M$9.74M-2.784Positive NewsGap DownPMVPPMV Pharmaceuticals3.0873 of 5 stars$1.01-5.2%$5.50+447.3%-22.4%$52.21MN/A-0.8550News CoveragePositive NewsCELUCelularity0.1759 of 5 stars$2.16+10.2%N/A-32.6%$51.71M$54.22M-0.81220News CoverageGap UpKLRSKalaris TherapeuticsN/A$2.73+2.2%N/AN/A$51.05MN/A0.00110Positive NewsGap UpCUECue Biopharma4.099 of 5 stars$0.68-0.8%$3.00+343.1%-29.8%$51.01M$7.99M-1.0160News CoverageIPAImmunoPrecise Antibodies1.7684 of 5 stars$1.10+3.3%$4.00+265.3%+33.5%$49.65M$18.16M-0.9480News CoverageBLUEbluebird bio2.1495 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News Coverage Related Companies and Tools Related Companies IFRX Alternatives AVTX Alternatives OTLK Alternatives CRVO Alternatives PMVP Alternatives CELU Alternatives KLRS Alternatives CUE Alternatives IPA Alternatives BLUE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERNA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
